Back to Search Start Over

Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients.

Authors :
Tong D
Heinze G
Pils D
Wolf A
Singer CF
Concin N
Hofstetter G
Schiebel I
Rudas M
Zeillinger R
Source :
BMC cancer [BMC Cancer] 2010 Dec 15; Vol. 10, pp. 682. Date of Electronic Publication: 2010 Dec 15.
Publication Year :
2010

Abstract

Background: Gene expression of peripheral myelin protein 22 (PMP22) and the epithelial membrane proteins (EMPs) was found to be differentially expressed in invasive and non-invasive breast cell lines in a previous study. We want to evaluate the prognostic impact of the expression of these genes on breast cancer.<br />Methods: In a retrospective multicenter study, gene expression of PMP22 and the EMPs was measured in 249 primary breast tumors by real-time PCR. Results were statistically analyzed together with clinical data.<br />Results: In univariable Cox regression analyses PMP22 and the EMPs were not associated with disease-free survival or tumor-related mortality. However, multivariable Cox regression revealed that patients with higher than median PMP22 gene expression have a 3.47 times higher risk to die of cancer compared to patients with equal values on clinical covariables but lower PMP22 expression. They also have a 1.77 times higher risk to relapse than those with lower PMP22 expression. The proportion of explained variation in overall survival due to PMP22 gene expression was 6.5% and thus PMP22 contributes equally to prognosis of overall survival as nodal status and estrogen receptor status. Cross validation demonstrates that 5-years survival rates can be refined by incorporating PMP22 into the prediction model.<br />Conclusions: PMP22 gene expression is a novel independent prognostic factor for disease-free survival and overall survival for breast cancer patients. Including it into a model with established prognostic factors will increase the accuracy of prognosis.

Details

Language :
English
ISSN :
1471-2407
Volume :
10
Database :
MEDLINE
Journal :
BMC cancer
Publication Type :
Academic Journal
Accession number :
21159173
Full Text :
https://doi.org/10.1186/1471-2407-10-682